Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors.

Anastasiya S Sokolova, Olga I Yarovaya, Lana V Kuzminykh, Anna A Shtro, Artem M Klabukov, Anastasia V Galochkina, Yulia V Nikolaeva, Galina D Petukhova, Sophia S Borisevich, Edward M Khamitov, Nariman F Salakhutdinov
{"title":"Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors.","authors":"Anastasiya S Sokolova,&nbsp;Olga I Yarovaya,&nbsp;Lana V Kuzminykh,&nbsp;Anna A Shtro,&nbsp;Artem M Klabukov,&nbsp;Anastasia V Galochkina,&nbsp;Yulia V Nikolaeva,&nbsp;Galina D Petukhova,&nbsp;Sophia S Borisevich,&nbsp;Edward M Khamitov,&nbsp;Nariman F Salakhutdinov","doi":"10.3390/ph15111390","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) causes acute respiratory infections, thus, posing a serious threat to the health of infants, children, and elderly people. In this study, we have discovered a series of potent RSV entry inhibitors with the (-)-borneol scaffold. The active compounds <b>3b</b>, <b>5a</b>, <b>5c</b>, <b>7b</b>, <b>9c</b>, <b>10b</b>, <b>10c</b>, and <b>14b</b> were found to exhibit activity against RSV A strain A2 in HEp-2 cells. The most active substances, <b>3b</b> (IC<sub>50</sub> = 8.9 μM, SI = 111) and <b>5a</b> (IC<sub>50</sub> = 5.0 μM, SI = 83), displayed more potency than the known antiviral agent Ribavirin (IC<sub>50</sub> = 80.0 μM, SI = 50). Time-of-addition assay and temperature shift studies demonstrated that compounds <b>3b</b>, <b>5a</b>, and <b>6b</b> inhibited RSV entry, probably by interacting with the viral F protein that mediated membrane fusion, while they neither bound to G protein nor inhibited RSV attachment to the target cells. Appling procedures of molecular modeling and molecular dynamics, the binding mode of compounds <b>3b</b> and <b>5a</b> was proposed. Taken together, the results of this study suggest (-)-borneol esters to be promising lead compounds for developing new anti-RSV agents.</p>","PeriodicalId":520747,"journal":{"name":"Pharmaceuticals (Basel, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697025/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals (Basel, Switzerland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph15111390","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Respiratory syncytial virus (RSV) causes acute respiratory infections, thus, posing a serious threat to the health of infants, children, and elderly people. In this study, we have discovered a series of potent RSV entry inhibitors with the (-)-borneol scaffold. The active compounds 3b, 5a, 5c, 7b, 9c, 10b, 10c, and 14b were found to exhibit activity against RSV A strain A2 in HEp-2 cells. The most active substances, 3b (IC50 = 8.9 μM, SI = 111) and 5a (IC50 = 5.0 μM, SI = 83), displayed more potency than the known antiviral agent Ribavirin (IC50 = 80.0 μM, SI = 50). Time-of-addition assay and temperature shift studies demonstrated that compounds 3b, 5a, and 6b inhibited RSV entry, probably by interacting with the viral F protein that mediated membrane fusion, while they neither bound to G protein nor inhibited RSV attachment to the target cells. Appling procedures of molecular modeling and molecular dynamics, the binding mode of compounds 3b and 5a was proposed. Taken together, the results of this study suggest (-)-borneol esters to be promising lead compounds for developing new anti-RSV agents.

Abstract Image

Abstract Image

Abstract Image

含n(-)-冰片酯类呼吸道合胞病毒融合抑制剂的发现。
呼吸道合胞病毒(RSV)引起急性呼吸道感染,对婴幼儿、儿童和老年人的健康构成严重威胁。在这项研究中,我们发现了一系列具有(-)-冰片支架的有效的RSV进入抑制剂。活性化合物3b、5a、5c、7b、9c、10b、10c和14b在HEp-2细胞中表现出抗RSV A A2株的活性。其中活性物质3b (IC50 = 8.9 μM, SI = 111)和5a (IC50 = 5.0 μM, SI = 83)的效价高于已知的抗病毒药物利巴韦林(IC50 = 80.0 μM, SI = 50)。添加时间测定和温度变化研究表明,化合物3b、5a和6b可能通过与介导膜融合的病毒F蛋白相互作用抑制RSV的进入,而它们既不与G蛋白结合,也不抑制RSV与靶细胞的附着。应用分子模拟和分子动力学方法,提出了化合物3b和5a的结合模式。综上所述,本研究结果表明(-)-冰片酯是开发新型抗rsv药物的有希望的先导化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信